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Medicine, New Haven, CT.
The purpose of this study was to determine the prevalence of the factor V
Leiden mutation among black and non-black inpatients and outpatients at the
Yale-New Haven Hospital.

We had found no previous information on the

prevalence of this mutation within the black population, although it had
been predicted by some that the abnormality might be found predominantly
in individuals of European extraction.

Randomly selected blood samples

were obtained from the Yale-New Haven Hospital hematology laboratory and
ethnic background was determined from hospital records.

In addition, we

studied stored DNA samples from black individuals already available in the
laboratory from previous population studies.

Using previously described

methods, genomic DNA was isolated and analyzed by PCR and restriction
enzyme digestion to identify the factor V cleavage site gene associated with
activated Protein C (APC) resistance.

Results were obtained on 214 black

individuals, of whom 3 (1.4%) were heterozygous for the Factor V Leiden
mutation. The incidence of the mutation in a similarly selected group of 126
non-black patients was 1.6%, yielding a relative risk of 0.88 (Fisher Exact twotailed test, P=1.0000, 95% confidence interval 0.12 to 7.64).

These results do

not support the hypothesis of a difference between the prevalence of the
Factor V Leiden mutation in the black and non-black populations studied.
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Introduction
Overview
Today we have a solid understanding of the physiology of blood
coagulation in normal, healthy subjects. The clotting cascade - that dreaded
maze of arrows and roman numerals which students diligently memorize in
anticipation of exams - appears in textbooks as a gospel of established fact, and
there is little mystery to the process in which blood turns from liquid to solid
when vessels are damaged.
We know considerably less about the reasons why blood clots in
apparently healthy tissue. Venous thromboembolism has presented clinicians
with diagnostic and therapeutic challenges for generations.

It is a common

source of morbidity and mortality, with an annual incidence of approximately
1 in 1,0002.

However, its molecular cause is rarely identifiable.

deficiencies of the natural

anticoagulant

factors - Protein

Inborn

C, Protein

S,

Antithrombin III - and dysfibrinogenemia can be found in 5-10% of patients
with venous thrombosis.345 The majority remain idiopathic.
This changed somewhat in 1993 and 1994, with the publication of a
series of elegant papers that demonstrated the presence of a previously
unknown

mutation in the gene for factor V.714

This mutation

quickly

became known as "factor V Leiden," in honor of the city in the Netherlands
where it was elucidated. Initial studies indicated that factor V Leiden was far
more prevalent among the general population than dysfibrinogenemia or
deficient Protein C, Protein S, or Antithrombin III combined. Factor V Leiden
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was also found in many more patients with venous thrombosis than the
previous disorders, so the wide gulf of "idiopathic hypercoagulation" was
narrowed considerably by the identification of this mutation.
However, these initial studies were conducted in northern Europe, and
at that time it was not clear whether the mutation was present to the same
extent in other ethnic groups - for instance, American blacks. Our study was
designed to address this question.
In order to place this experiment in its proper context, we should first
consider the mutation's physiology and clinical significance.

What is Factor V?
Factor V was first described independently by Dr. Armand J. Quick in
1943, and by Dr. Paul A. Owren in 1947.15 Quick noticed that the prothrombin
time (PT) of plasma would increase after the sample was stored on a shelf for
more than eight days.lh He found that the PT would then return to norma! if
he

added

plasma

from

experimental

animals

to

the

stored

sample.

Prothrombin had been described since the early 1930s,17 and Quick recognized
that this chemical in the donor animal's plasma might be responsible for the
normalization of prothrombin time.
bishydroxycoumarin to the

To eliminate this possibility, he fed

donor animals, which would inactivate their

own prothrombin activity. Even then, the normalization of stored plasma's
PT persisted. He therefore postulated the existence of a "labile factor" in the
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plasma distinct from prothrombin, which was lost during storage, but which
would foster clot formation in life.
For Owren,

the

inspiration

to consider the

possibility

of

a

new

coagulation factor came in the form of a single patient, an unfortunate young
woman with a lifelong tendency to bleed heavily.18 Her prolonged PT could
be normalized with donated, prothrombin-depleted plasma. This led him to
conclude that she had a deficiency of some compound

which

he called

"proaccelerin," since it sped up the PT. Because four proteins involved in the
clotting process had already been described, he referred to proaccelerin as the
"fifth coagulation factor," synonymous with today's "factor V."
The structure and function of Factor V have subsequently been welldescribed.19 23 Indeed, the gene for factor V has been mapped to chromosome
one (lq21-25),24

and its DNA sequence was published more than a decade

ago.23 A brief review of Factor V physiology and regulation will be helpful
before describing the Leiden mutation.
Factor V serves a crucial role in the clotting cascade. A linchpin at the
intersection of the "intrinsic" and "extrinsic" pathways of coagulation, it
functions as a potent pro-coagulant (see Figure 1).
When vessels are injured, tissue factor becomes exposed, and interacts
with

factor

VII,

thrombin.1617 26

leading

Thrombin

to

the

conversion

of

prothrombin

into

then activates platelets, converts fibrinogen to

fibrin, and activates factors V and VIII.

Under normal conditions, factor V

circulates

biologically

in

the

bloodstream

as

a

inactive

single

chain

4

Figure 1. Schematic representation of the coagulation cascade. Inhibition reactions
are indicated by dashed arrows. Notice that factors Va and Xa participate together
in a reaction that is common to clotting that originates in either the intrinsic or ex¬
trinsic pathways, and thus are part of the "final common pathway." Adapted from
Stieve-Martin EA, Lotspeich-Steininger CA, Koepke JA (eds): Clinical Hematology.
Philadelphia, 1998, p.614.
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glycoprotein with a molecular

weight of 330,000.23

It remains

in

this

"dormant" state until it comes in contact with either thrombin or activated
factor X (factor Xa).

Although

thrombin

activates

factor V

at a

rate

approximately 100 times faster than factor Xa, the latter probably serves a
more important role in the early stages of coagulation, when little thrombin
has yet been generated.27 Both of these enzymes cleave factor V into factor Va,
a heterodimer whose heavy chain (Mr = 94,000) and light chain (Mr = 74,000)
are bound non-covalently by Ca2+ ions.23

Once activated, factor Va binds to

activated platelets and becomes a receptor and cofactor for factor Xa.

When

factor Xa binds to factor Va, they together form a cleavage enzyme called
"prothrombinase."

Prothrombinase

breaks prothrombin

into

thrombin,

which will in turn activate more factor V, a cycle leading to the rapid
amplification of the clotting cascade.22
Therefore, very small

amounts of factor Va

lead to tremendous

acceleration of the formation of platelet-fibrin clots.

Without

clotting

potential:

happens

at

only

a

small

fraction

of

its

prothrombinase breaks prothrombin into thrombin

factor Va,
complete

103 times faster than

factor Xa alone.28

How is FactorV Regulated?
Factor Va's action is kept under strict control by an elegant series of
enzymatic interactions.282W30 Although thrombin serves to activate factor V in

The plasma concentration of Factor V has been measured at approximately 10 mg/liter.26
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damaged vessels, it has the opposite function in healthy ones, due to its
interaction with a protein called thrombomodulin. Thrombomodulin

is a

multi-modular protein of 557 amino acids with a trans-membrane domain
that anchors it to the luminal
lymphatic endothelial cells.

surface of arterial, capillary, venous,

It is found in highest concentration

and

in the

microcirculation, where the ratio of endothelial cell surface area to blood
volume is 1,000 times that in the great vessels.2b
Thrombomodulin
bloodstream,

and

protrudes

functions

from

the

vessel

as a receptor for thrombin.

wall
As

into

the

thrombin

circulates in the blood and enters capillaries, it binds to thrombomodulin.
Once bound, thrombin no longer participates in clotting reactions; rather, it
serves as an activator of another soluble protein called protein C.
The first attempts to purify protein C took place in I960,1' and today its
structure and function are understood on a molecular level.

It is a vitamin

K-dependent zymogen comprised of a heavy chain and a light chain, with a
molecular weight of 62,000 kDa. When protein C contacts the thrombin that
is bound to thrombomodulin, its heavy chain is cleaved at a specific site near
the amino terminus. This reaction exposes a Serine protease domain on the
protein C molecule, converting it into a powerful cleavage enzyme referred to
as "activated protein C" (APC) (see Figure 2). The protease action of APC is
specific for three sites on the heavy chain of the factor Va heterodimer: when
APC encounters factor Va, it cleaves the peptide bonds of the heavy chain at
those sites, rendering it inactive as a cofactor for factor Xa. This process is
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enhanced by the presence of protein S, a co-factor for APC whose precise
mechanism of action remains unclear, and by factor V itself (see Figure 3).
In contrast, when

protein C encounters

thrombin

not

thrombomodulin, its activation is 20,000 times less efficient.

bound

to

This serves to

prevent the activation of protein C at sites of vascular injury, where there is
an appropriately higher proportion of free, unbound

thrombin,

therefore

allowing the pro-coagulant action of factor Va to predominate where it its
needed.
In summary, factor V serves as a potent pro-coagulant when activated
by cleavage at a specific site by thrombin or factor Xa.

Factor Va activity, in

turn, is regulated by the specific proteolytic action of APC at three different
sites.

The activity of APC is in turn downregulated at sites of vascular

endothelial damage, because activation of protein C is much slower in the
presence of thrombin which is not bound to thrombomodulin.

What is Factor V Leiden?
In

1993

responsiveness
thrombosis.7

Dahlback

et

al

to

in

some

APC

described
patients

the

phenomenon

who

experienced

of

poor

venous

In this study, the activity of protein C was tested in vitro by

adding APC to the reagents used to determine the partial thromboplastin
time

(PTT), a test of the

coagulation.

intrinsic

and

the final

common

pathway

of

Because APC serves as an anti-coagulant, its addition to this

reaction would be expected to increase the PTT. By comparing the PTT with
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minM
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Figure 2. Schematic representation of the activation of protein C. Thrombin
(T) circulates in the blood until it binds with thrombomodulin (TM), protruding
from the vascular endothelium. Once bound, thrombin is able to bind protein
C (pC) and enzymatically expose its serine protease moiety, thus converting it
into activated protein C (APC), which can participate in the activation of factor V.
Adapted from Dahlback B: Inhertited thrombophilia: Resistance to activated
protein C as a pathogenic factor of venous thromboembolism (review).
Blood 85:607-14, 1995.

Figure 3. Model of the process by which the heavy chain of activated factor V (fVa)
is broken into its inactivated form (fVi) by the proteolytic action of activated protein
C (APC), with its cofactors protein S (pS) and factor V (fV). Events are believed to
take place on the surface of phospholipid membranes. Adapted from Dahlback B:
Inhertited thrombophilia: Resistance to activated protein C as a pathogenic factor
of venous thromboembolism (review). Blood 85:607-14, 1995.
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and without the addition

of APC, a patient's response

quantified as the ratio between the two assays.

to APC can be

Dahlback et al identified an

individual with a strong personal and family history of multiple venous
thromboses, and tested him and his family members for APC resistance in
this manner. Among nineteen subjects tested, fourteen were found to have
only a minimal increase in the PTT, placing them below the fifth percentile of
control values. In other words, their blood was resistant to the anti-coagulant
effects of APC. This observation was repeated in other studies; APC resistance
was demonstrated again in 64 of 301 patients with thrombosis,8 in 33% of 104
consecutive patients with a personal history of thrombosis.14

The authors

who first observed this phenomenon made the reasonable speculation that
APC resistance might be explained by an inherited deficiency of some yetundescribed cofactor for protein C.
Alternatively, it was postulated that the defect might lie in the targets
of APC: factor V or factor VIII.

In a study conducted by a team in the

Netherlands,8^ patients with deep vein thrombosis and APC resistance were
identified.

Linkage

analysis

between

the

APC

resistance

trait

and

polymorphisms of the genes for various clotting factors revealed that APC
resistance segregated with factor V but not factor VIII or von Willebrand
factor, and therefore factor V became the focus of investigation.
patients' DNA encoding for factor V was analyzed.

These

Careful sequencing and

RFLP revealed the presence of a previously-unknown

missense mutation

which converted guanine to adenine at nucleotide 1,691 in the factor V
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sequence. This in turn leads to a change in the codon sequence such that an
arginine residue is replaced by a glutamine residue (CGA for arginine is
replaced by CAA for glutamine).

Because this residue is found at one of the

three critical sites for proteolysis by APC, and because glutamine's acidic side
chain renders it resistant to cleavage by the APC serine protease, the activated
form of factor V Leiden is inactivated by APC at a much

decreased rate.

Therefore, it remains able to potentiate the clotting cascade even under
circumstances in which it would normally be inactivated.

Clinical Significance of Factor V Leiden
The robust pro-coagulant function

of factor V Leiden leads to an

increased risk of venous thrombosis for patients who carry it, particularly
those with other identifiable risks for hypercoagulability. In the few years that
have followed the elucidation of factor V Leiden, its implications for patients
with a number of clinical conditions have been investigated, such as protein
C deficiency.

In order to determine whether factor V

Leiden

plays an

additional role in thrombotic complications among patients known to have
deficient protein C, Koeleman et al studied the segregation of the mutation
and APC deficiency.31

Out of 48 symptomatic

patients with

deficiency, they detected 9 (19%) with factor V Leiden.
families studied, 31%

of subjects with

protein

C

Furthermore, in six

protein C deficiency developed

thrombosis, and 13% of subjects with factor V Leiden developed thrombosis;
however, 73% of subjects with both conditions developed thrombosis, a
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statistically-significant increase in risk.

Although heterozygous protein C

deficiency is itself found in only 0.1-0.5% of healthy blood donors,32 these data
suggest that it can have significant clinical implications when

present in

combination with factor V Leiden.
Factor V Leiden also fosters thrombosis in patients with other, far more
common risk factors. For example, this mutation has an important impact
on patients who use oral

contraceptive

pills (OCPs).

OCPs have

been

associated with as increased incidence of venous thrombosis since their first
use

in

the

1960s:

it

has

been

calculated

that

the

incidence

of

thromboembolism among fertile, healthy women who did not use OCPs was
approximately one in 20,000, whereas this value increased to one in 3600
among

comparable women

using

the early generation

of OCPs.33

An

increased risk persists even among users of later-generation OCPs, and the
presence of factor V

Leiden appears to greatly compound

this risk, as

demonstrated by Vandenbroucke et al.M Their retrospective analysis focused
on 155 consecutive premenopausal women, aged 15 to 49, who had developed
deep venous thrombosis in the absence of other underlying diseases. When
compared with 169 population controls, subjects who used OCPs were four
times more likely to develop a DVT, and subjects who later tested positive for
factor V Leiden were eight times more likely. Those who both took OCPs and
had factor V Leiden had a relative risk of 34.7 for experiencing thrombosis (Cl
7.8-154).

These data, and other series that corroborated them,35 37 spurred a

debate as to whether asymptomatic women should be screened for factor V
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Leiden before beginning OCPs.38'39 Considering the fact that approximately 9.9
million American
question.

women

rely on oral contraception,40 this is no small

To date, a consensus seems to have been reached that general

screening is not indicated.

Cost-benefit analysis suggests that testing all

patients for factor V Leiden before prescribing OCPs would be prohibitively
expensive,41 and should be reserved for those with a clear medical or family
history of thrombosis.
Cigarette smoking may be another risk factor for thrombosis that is
exacerbated by the presence of factor V Leiden. Among 84 women age 18 to 44
who experienced a first myocardial infarction (MI), 10% were heterozygous
for factor V

Leiden, as compared with 4% of 388 age-matched

controls,

yielding an overall odds ratio for the development of MI among factor V
Leiden carriers versus non-carriers of 2.4 (95%

Cl 1.0 to 5.9).42

Closer

inspection revealed an interesting trend: the mutation had little effect among
non-smokers, with an odds ratio for the development of Ml among non¬
smoking factor V Leiden carriers versus non-smoking non-carriers equal to
1.1 (95% Cl 0.1 to 8.5).

However, among smokers the presence of factor V

Leiden was a significant additional risk factor, with an odds ratio of 3.6 (95%
Cl 0.9 to 14.4), and a 32-fold increase in the risk of MI among smoking carriers
versus non-smoking non-carriers.
Links have also been established between factor V Leiden and the
Budd-Chiari

syndrome,43 44 childhood

ischemic

stroke,45 46

fetal

loss

and

preeclampsia,47 retinal vein occlusion,48 and venous thromboembolism in
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concert with hyperhomocysteinemia.49 Even when we ignore the mutation's
synergistic effects with other identified risk factors, such as OCPs and protein
C deficiency, the overall risks it poses are impressive.

In the original Leiden

thrombophilia study,8 301 patients with deep vein thrombosis were tested for
APC resistance by modified PTT assay.

21% of these patients demonstrated

APC resistance, as compared with 3% of control subjects.

When the factor V

Leiden mutation was identified the following year, those same APC resistant
patients were tested for the presence of factor V Leiden: 47 were heterozygous
and 6 were homozygous, as compared to three heterozygous controls.9 It was
therefore predicted that heterozygotes are at 5- to 10-fold the risk of venous
thrombosis of non-carriers, and that homozygotes are at a 50- to 100-fold
risk.26

The Question of Prevalence
From

the

earliest

surprisingly common,
thrombosis,

but also

investigations,

not only
among

among

the

factor V

Leiden

seemed

patients suffering from

general

thrombophilia study,8 64 of 301 consecutive

population.

In

the

to

be

venous
Leiden

Dutch patients with venous

thrombosis tested positive for factor V Leiden, as did 14 of 301 healthy
controls, suggesting a prevalence of about 5%.
general

population

in

various

countries

Subsequent studies of the

demonstrated

a

peak

carrier

frequency of 13.4% in Greece911 and 10.9% in Sweden,51 with prevalence in
other European nations ranging from 2.7% in Italy50 to 6.8% in the United
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Kingdom,52 for a cumulative European average prevalence of 5.4%,53 making
factor V Leiden by far the most common identified hereditary risk for venous
thrombosis.26
But as of the summer

of 1995, we found no information

prevalence of this mutation in the American black population.
earliest studies of factor V
American

individual,10 but

population-based study.
might

be

responsible

One of the

Leiden reported its presence in one
this

observation

was

not

on the

African

quantified

in

a

It had been proposed in 1994 that a founder effect
for

the

mutation's

high

prevalence,

because

a

disproportionate number of factor V Leiden carriers were also carriers for a
marker allele: when digested with Hinil, the DNA from 96% of 53 factor V
Leiden carriers also had a cytosine at nucleotide 2,298, whereas only 73% of 69
non-carriers had this base pair (x2diff = 30.4, d.f. =1; P<0.001).°

However, this

analysis is not conclusive proof of a founder effect, nor does it serve as a
guarantee of the mutation's absence among American blacks. Although the
mutation's molecular nature was understood, and its clinical implications
had begun to be quantified, its prevalence among American blacks remained
unknown.
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Statement of Purpose

At the time our study was conducted. Factor V Leiden had recently
been described as the most common
thrombosis in Caucasian patients.

identifiable genetic risk for venous
However, we found no data on

mutation's prevalence among American blacks.

the

Therefore, the purpose of

this study was to determine the prevalence of the Factor V Leiden mutation
among non-selected black and non-black inpatients and outpatients at the
Yale-New Haven Hospital. Our null hypothesis was that the mutation would
not be detected among black patients to the same degree that it was detected
among non-black patients.
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Methods
Overview
In this study we chose samples of

blood from the YNHH clinical

hematology laboratory, identified the samples by ethnicity, extracted DNA
from the blood, amplified a pre-determined portion of the gene for Factor V
using the

polymerase

chain

reaction

(PCR), digested that DNA with a

restriction enzyme, and used the restriction fragment length polymorphism
(RFLP) to determine the presence or absence of the Factor V Leiden mutation.
The techniques used were adapted from those described by Bertina et al9 and
Koeleman et al,31 and can be summarized as follows:
CHOOSE BLOOD SAMPLES

\7
IDENTIFY BLOOD BY ETHNICITY

V
EXTRACT DNA FROM WHOLE BLOOD

V
AMPLIFY FACTOR V DNA CLEAVAGE SITE
with PCR

\7
DIGEST PCR PRODUCT
with Mnl-I

\7
DETERMINE PRESENCE OR ABSENCE
of FACTOR V LEIDEN
with AGAROSE GEL ELECTROPHORESIS
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Preparation
A proposal to conduct this study was submitted to the Yale University
School of Medicine's Human Investigations Committee.

Permission

was

granted to proceed, with the understanding that the identities of participants
would

remain

participation,

secret.
and

none

No

study

subjects

would be contacted

would
at any

be

aware

time,

of

their

regardless of

individual results.
The YNHH admissions staff agreed to provide access to computerized
hospital records. The hematology laboratory staff agreed to provide access to
stored blood samples.
Dr. Berliner, Dr. Sigurdsson, and I agreed that this research would be
conducted by me under their close supervision; unless otherwise indicated, I
performed all of the hands-on work herein.

Patient Selection
Participants in this study were selected in one of two manners:
A. The hospital's clinical hematology laboratory routinely refrigerates
tubes of blood for one week after they are drawn and analyzed, and these
"remnant" blood samples were made available to us.
these anonymous

blood samples by ethnic

In order to identify

background,

I first used the

hematology laboratory computer to generate a list in chronological order of
inpatients and outpatients whose blood had been drawn for unspecified
assays after twelve noon

on the previous day.

The ethnicities of these
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individuals was then

verified

using

the

hospital

admissions

laboratory

computer, because all patients at Yale are required upon admission to describe
their own ethnicity by choosing from the following categories: white, black,
Spanish-American, Asian, Pacific Islander, Native American, or other.

With

knowledge of the patients' ethnicities, I then returned to the hematology
laboratory to select appropriate blood samples for our study.

Appropriate

samples were at least 2cc of liquid whole blood in intact EDTA-anticoagulated
VacutainersR ("lavender-top tubes").

Over the course of several weeks, 180

blood samples were obtained from patients who had described themselves as
"black," and 188 from control patients who did not describe themselves as
"black"(166 "white," 15 "Spanish-American," 3 "Asian," 4 "other"). 1 recorded
the donors' ethnicities, and numbered these samples in the order in which
they were processed. All subsequent products of DNA analysis were labeled
and referred to by these unique study numbers.
B. The research laboratory of Dr. Bernard Forget contains a bank of
DNA from patients who have participated in unrelated population studies.
Some of these are black patients who have been diagnosed with either
hereditary

spherocytosis

or

hereditary

eliptocytosis.

Their

DNA

was

meticulously extracted by Dr. Forget's staff, using the "by hand" technique
described below. Forty-five of these DNA concentrates were sampled under
sterile technique, consecutively labeled, and included in the study group.

19

Extraction of DN A
DNA was extracted from whole blood by one of two methods:
OIAamp Protocol
In order to process high numbers of samples in a shorter time, 1 used
the "QIAamp Blood Kit," manufactured by Qiagen.'

Blood was processed

according to the instructions which came with the kit. Each of the following
steps was performed in a sterile fashion.
1) Blood in a lavender top (EDTA) tube was obtained from the YNHH clinical
hematology laboratory, as described above.

Blood was stored at 4°C until

processed.
2) To increase the yield of DNA from whole blood, white blood cells were
separated by centrifugation to obtain a buffy coat.
agitating the sample on an automated

This was done by gently

tilt table for five

minutes,

then

withdrawing 1.5ml into a 1.7ml eppendorf tube, and spinning at 4500g for 20
minutes.
3) 200k of buffy coat was transferred into a new 1.7ml eppendorf tube.
4) To the buffy coat was mixed with 25A. proteinase (either QIA Protease or

generic

Proteinase

K

at

lOpg/ml)

and

200?v

buffer

AL,

and

vortexed

immediately for ten seconds.
5) The sample was then incubated at 70°C for 10 minutes, either on a heating
block or in a hot water bath.
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6) The sample was then incubated at 95°C for an additional 15 minutes.

This

step was intended to deactivate the proteinase and kill any contaminating
microbes.
7)

The tube cooled for approximately five minutes, and then 2107. 100%

isopropyl alcohol was added. The solution was vortexed.
8)

The solution

was transferred into a proprietary QiagenB

filter

“spin

column." This column was then placed in a 2ml collecting tube. The column
and collecting tube were spun together at full speed for one minute, sending
the liquid contents of the solution

into the tube, and leaving the DNA

behind.
9) The column and DNA were transferred to

a clean collection tube.

The

used collection tube was discarded.
10) The column was washed with 5007. proprietary Buffer AW.

The tubes

were spun at full speed for one minute, sending the buffer wash into the
collection tube and leaving the DNA behind.
11) The collection tube was discarded and replaced with a sterile one, again
washed with 5007. proprietary Buffer AW.

This time the tube was spun at

full speed for two minutes.
12) The used collection tube was discarded, and the column was transferred
to a sterile 1.7ml eppendorf tube.
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13) 200X T.E., preheated to 70°C, was added to the spin column. When spun at
full speed for one minute, the T.E. carries the DNA residue with it into the
collection tube.
14)

To verify that this process succeeded in extracting DNA, 7k of the

DNA/T.E. solution was mixed with 3k of loading buffer containing marking
dyes.

Samples were then analyzed on a standard 1%

ethidium bromide at lOOmv for approximately 30 minutes.

agarose gel with
If present, DNA

would show up as a sharp, intense, high-molecular-weight band.
15) DNA was stored in the short run at 4°C, and at -20°C once PCR analysis
was complete (see below).

Triton X Protocol
Early in our study DNA from 24 subjects was extracted with

the

following method.
1) Blood in a lavender top (EDTA) tube was obtained from the YNHH clinical
hematology laboratory, as described above.

Blood was stored at 4°C until

processed.
2) Triton X solution was prepared as follows:
0.32 M Sucrose
10 mM Tris HC1, pH 7.5
5 mM MgCl2
1% Triton X 100

109.5 g/L
10 cc/ L of 1 M Stock
5 cc/L of 1 M Stock
lOcc/L

Solution was autoclaved and stored at 4°C.
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3) 5 cc whole blood was transferred into a 50 ml conical tube. Tube was filled
to 50 ml with Triton X solution precooled to 4°C, then

mixed by gentle

shaking.
4) Mixture was spun at 1000 g for 10 minutes at 4°C.
5) Supernatant was discarded. Nuclear pellet could then be frozen at -70°C
and stored indefinitely.
6) 1 liter of RSB solution as follows:
1M Tris
5M NaCl
0.5M EDTA
10% SDS
H20

10 ml
20 ml
20 ml
50 ml
900 ml

7) Nuclear pellet was resuspended in 5 ml RSB.
8)

Proteinase K was added at 200 jig/ml, and the solution was incubated

overnight at 37°C.
9) 2.5 ml phenol and 2.5 ml chloroform were added to the tube.

Tube was

agitated gently. After the formation of an aqueous-organic fluid level, the top
layer was discarded.
10) Step nine was repeated once.
11) To achieve better purification, 5 ml chloroform was added to the tube.
Tube was agitated gently.

After the formation of an aqueous-organic fluid

level, the top layer was discarded.
12) Step eleven was repeated once.
13) 0.5 ml 3 M NaOAc was added.
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14) DNA was precipitated with 13 ml 100% EtOH.
15)

A plOOO pipetman was used to move

precipitate into a fresh 1.7 ml

eppendorf tube.
16) Precipitate was washed with 70% EtOH, and allowed it to air dry.
17) Precipitate was re-suspended in 1.5 ml T.E.
18)

To verify that this process succeeded in extracting DNA, 77. of the

DNA/T.E. solution was mixed with 37. loading buffer containing marking
dyes. I then ran this mixture on a standard 1% agarose gel with ethidium
bromide at lOOmv for approximately 30 minutes.

If present, DNA would

show up as a sharp, intense, high-molecular-weight band.
19) DNA was stored in the short run at 4°C, and at -20°C once PCR analysis
was complete (see below).

Amplification of

Factor V APC cleavage site with PCR

In order to determine whether the Factor V Leiden mutation

was

present or absent in a given subject's DNA, it was necessary to analyze the
RFLP pattern of the DNA that encoded for the APC cleavage site.
step in this analysis involved

The first

the amplification of that site via PCR, as

follows:

1)

DNA primer oligonucleotide primers were synthesized.

These primers

were the same as those used by Bertina et a l9 in their analysis of the factor V
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Leiden mutation. They served to amplify a segment of the gene for factor V
that includes the APC cleavage site.
The primers had the following sequence:
3': CTTGAAGGAAATGCCCCATTA
5': TGCCCAGTGCTTAACAAGACCA
2)

A master mix of ingredients for PCR was prepared according to the

number of tubes to undergo the process. Each tube contained the following
sterile ingredients:
0.5X DNA (obtained from either the QIAamp protocol or the Triton X
protocol outlined above).
0.2 U / X Taq Polymerase

0.25X

0.1pg/X 3'oligo

IX

0.1 qg/ X 5'oligo

IX

10X buffer

5X

2 mM dNTPs

5X

25 mM MgCL,

10X (This is equivalent to a 5mM solution.)

H2Q_30 X
52.75X Total Volume
In addition to the tubes containing study DNA, one tube contained no DNA
("negative

control

tube") and one

tube contained

DNA that had been

amplified successfully on previous occasions ("positive control tube").
3) These tubes were subjected to PCR according to the following program:
Denature at 91°C x 40 seconds
Anneal at 60°C x 40 seconds
Extend at 71°C x 1 minute
Repeat x 30 cycles
Extend at 71°C x 5 minutes
Soak at 4°C until tubes are removed from machine

25

4) 6X PCR product was mixed with 2X loading buffer containing marking dyes
and electrophoresed through a

1% agarose gel with ethidium bromide for

approximately 20 minutes. A base-pair "ladder" of Hindlll and 0X174 was run
in each gel to determine fragment length.

If present, the APC cleavage site

would appear as a band of 220 base pairs.
5)

If the negative control lane displayed any bands, the experiment was

considered contaminated, and all PCR products were discarded.
6) If no bands appeared in any lane, or if bands appeared with lengths other
than 220 base pairs, the

PCR products from

that tube were considered

contaminated, and were discarded.

Analysis of PCR Products with RFLP
RFLP analysis was performed in order to determine whether the patient's
amplified DNA was wild-type or factor V Leiden.
1) A master mix was prepared, and the PCR product was digested as follows:
3X 10X BSA
3X 10X Buffer

(New England Biolabs buffer #2)

0.5X Mnl-1

(New England Biolabs, Equivalent to 2.5 U)

20A, H20
4X. PCR product
30.5X total volume.
2) Tubes were spun briefly to move all fluid into the bottom.
3) Tubes were then incubated at 37°C for two hours.
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4) Digestion was visualized on 2% agarose gel as follows: 6X loading buffer
containing marking dyes was added to each tube, and the whole volume of
digestion (approximately 36X) was loaded into large wells in the gel. One lane
was loaded with

undigested PCR product (the

“negative

control"),

and

another was loaded with digested PCR product from a patient with known to
have Factor V Leiden (the “positive control"). A base-pair “ladder" was made
with HINDIII and 0X174 Electrophoresis was performed in TBE at 150 mv for
approximately 30 minutes.
5) The gel was visualized and photographed.
6) The predicted sizes of the digested PCR products from patients with wildtype factor V DNA are 163, 67, and 37 base pairs.

7) Because the factor V Leiden mutation destroys a restriction enzyme site
within this fragment, the predicted sizes of the digested PCR products from
patients with factor V Leiden DNA are 153 and 67 base pairs.

Therefore, the

difference between 153 base pairs and 67 base pairs was diagnostic for Factor V
Leiden. (See Figure 4.)
8) Any uncut DNA was found at 220 base pairs (matching the band found in
the “negative control" lane).

If 220 was the only band found in a lane, that

digestion was considered a failure, and more PCR product was digested and
visualized.
Time Course
This

research

was

conducted

in

June,

July,

and

August

of

1995.
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Figure 4. Appearance of an agarose gel slab after undergoing electrophoresis with
the DNA products of our experiment. A base-pair "ladder"was used at left to gage
the lengths of DNA fragments. Proper amplification of the factor V cleavage site
region yielded a band of 220 base pairs, and a faint band at the bottom of the gel,
representing oligonucleotides left over from the PCR process. After undergoing
digestion with the Mnl-I restriction enzyme, three patterns were possible: DNA
from patients with two wild-type copies of the factor V gene would appear as three
bands at 116, 67, and 37 base pairs; if patients were heterozygous for factor V Leiden,
a band of 153 base pairs would appear in addition to the three bands found in the
wild-type DNA; in patients who were homozygous for factor V Leiden, only bands
at 153 and 67 base pairs would be expected.
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Results
The blood of 188 anonymous patients who did not describe themselves
as "black" was obtained and analyzed as described above.

Of these samples,

four became contaminated, 45 were not amplified successfully via PCR, and
13 were not digested successfully with Mnl-I.

Of the remaining 126 samples,

124 were negative for the factor V Leiden mutation, two were heterozygous
positive, and none was homozygous positive.
The blood of 180 anonymous patients who described themselves as
"black" was obtained and analyzed as described above. Of these samples, three
became contaminated, five were not amplified successfully via PCR, and six
were not digested successfully with Mnl-1. Of the remaining 166 samples, 165
were negative for the factor V Leiden mutation,

one

was heterozygous

positive, and none was homozygous positive.
DNA from 49 patients who described themselves as "black" and had
participated in unrelated studies was obtained from another laboratory and
analyzed as described above.

Of these samples,

one

was not

digested

successfully with Mnl-I. Of the remaining 48 samples, 46 were negative for
the factor V Leiden mutation, two were heterozygous positive, and none was
homozygous positive.
In total, then, of the 214 samples from black patients that were analyzed
successfully, three (1.4%) tested positive for the factor V Leiden mutation.

By

comparison, the prevalence of the mutation in 126 samples from non-black
patients that were analyzed successfully was two (1.6%).
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Therefore, the relative risk of carrying a single copy of the factor V Leiden
Mutation is 0.88 (Fisher Exact two-tailed test, P = 1.0000, 95% confidence
interval 0.12 to 7.64). (See Table 1.)
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Table 1. Results were obtained for 214 Black individuals, of whom 3 (1.4%)
were heterozygous for the Factor V Leiden mutation. By comparison, the
prevalence of the mutation in a group of 126 non-Black patients selected in
the same manner was 2 (1.6%), yielding a relative risk of 0.88 (Fisher Exact
two-tailed test, 95% Cl 0.12 to 7.64, P = 1.0000). No patients were found to be
homozygous for factor V Leiden.
Statistical analysis was computed with Epi Info.c
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Discussion
These data do not support the hypothesis of a difference between the
incidence of the factor V

Leiden mutation

in

the

black and

non-black

populations studied. Rather, the proportion of these populations that carries
a single copy of the factor V Leiden allele is very close: 1.4% among blacks and
1.6% among non-blacks, a difference that is not statistically significant.
Other studies confirm approximately the same prevalence of factor V
Leiden among American blacks. Dilley et al54 tested for the prevalence of this
mutation in 93 non-selected blacks, and found one heterozygous carrier,
equivalent to a prevalence of 1.1%.
among

76

blacks

without

a

Hooper et al55 looked for the mutation

history

heterozygote, for a prevalence of 1.4%.

of

thrombosis,

and

found

one

Austin et aD assayed 130 African-

Americans, and found one who was heterozygous for factor V Leiden, for a
prevalence of 0.8%. The largest study to date on prevalence of the mutation
among African Americans was published by Ridker et al last year."7

In this

experiment, blood samples from 1,608 men participating in the Physicians'
Health Study and 2439 women participating in the Women's Health Study
were assayed using techniques of PCR and RFLP similar to those used in our
study.

Subjects

were free of myocardial

infarction,

stroke,

or

venous

thrombosis at time of enrollment. Six-hundred and fifty of them described
themselves as African-American; 1.23% tested positive for factor V Leiden.
(See Table 2.)
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Factor V Leiden Mutation
Carrier
Prevalence

95% Cl

211

1.4%

0.12-7.64

1

92

1.1%

Atlanta

1

75

1.4%

0.02-3.60

Austin (56)

Atlanta

1

129

0.8%

0.01-2.1

Ridker (57)

USA

8

642

1.2%

0.53-2.41

14

1,149

1.2%

Author (ref.)

Location

Yes

present study (1)

New Haven

3

Dilley (54)

Atlanta

Hooper (55)

Total

No

*

Table 2. Cumulative data from this and other studies of the prevalence of the
factor V Leiden mutation in non-selected patients who described themselves
as "black" or "African American." The total prevalence of 1.2% is close to the
1.4% found in our study.
However, our control data are not in agreement with the prevalence
found in other studies.

In the Ridker data, for instance, 2,468 participants

described themselves as Caucasian; 128 tested heterozygous positive for factor
V Leiden, and 2 tested homozygous positive, for a total carrier rate of 5.27%
(95% Cl 4.42 to 6.22). This is significantly different from our carrier rate; even
when only "white" controls are included, the carrier rate is 1.8% (110 subjects,
2 heterozygous positive). We have no explanation for this discrepancy.
As
prevalence

more
in

information
different

has

ethnic

become
groups

available

around

the

on

the

mutation's

world,

persuasive

Preliminary data published as an abstract at the 1995 annual conference of the American
Society of Hematology. No statistical analysis performed.
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hypotheses have been made regarding its evolutionary genetics.

Reviews

such as that by Rees53 compile evidence that points strongly to a single origin
of the mutation,

or "founder effect," with subsequent genetic mixing to

explain the mutation's existence in the new and old world.

For instance,

studies of more than 550 individuals from Sub-Saharan Africa have revealed
no carriers of factor V Leiden,53,58 a marked contrast from the prevalence in
American blacks, which would be consistent with genetic mixing rather than
separate de novo mutations in the old and new worlds.
If we wanted to apply our data to the question of whether factor V
Leiden is present in blacks because of the mixing of genetic information from
Europe or because of a de novo mutation, we would require extensive genetic
pedigrees from
participants,

all

nor

participants.
do

we

have

We

have

precise

no

pedigrees on

information

on

any

their

study
ethnic

backgrounds; we might imagine that patients of African, African-American,
Caribbean, or Latin heritage might describe themselves

as "black."

New

Haven does have a considerable African-American population, so it is not
unreasonable

to

postulate

that the

majority

of

patients

who

described

themselves as "black" would also describe themselves as "African-American"
if given that option.

However, we cannot take that assumption for granted.

So the question of where the factor V Leiden mutation came from is beyond
the scope of this study.
Nor was that our intention.

The origins and population drift of factor

V Leiden pose fascinating questions, but those were not our questions.
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Regardless of how or when Factor V Leiden entered the black population of
New Haven, our data show that it is present to a significant degree.
How, then, do we use this knowledge to best serve our black patients?
Does it make sense to seek the mutation in every black resident of New
Haven?

Apparently it does not.

It has been estimated

that the cost of

preventing one thromboembolic death by screening a general population
with a factor V Leiden prevalence of 2% would cost over $44 million.59
Furthermore, anticoagulating all factor V Leiden carriers would probably do
more harm than good, because the morbidity of lifelong warfarin therapy
would surpass the inherent thrombotic risk of the mutation.'"0,61 On the other
hand, it does not seem prudent or ethical to ignore these data. Some middle
ground

must

considered.

be sought,

in

which

individual

patient

risk

factors are

Patients with factor V Leiden should be counseled as to the risk

factors that it entails, as should their families.
So far, the risk factors among black carriers seem to be the same as
those in the non-black population.

At the time we conducted this study, it

was unknown whether the detection of factor V

Leiden among African

Americans would hold implications specific to that group.

For instance,

patients with sickle cell disease would seem to benefit from screening for
factor V Leiden; because both conditions are associated with abnormal blood
flow, a synergistic effect and

propensity

towards more

predicted. Interestingly, this has not been demonstrated.

crises might

be

Wright et al found

only one carrier of factor V Leiden among 165 patients with steady-state sickle
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cell disease.62

Kahn et al63 looked for factor V Leiden in 82 patients with

either HgbSS, SC, or S-beta thalassemia, 19 of whom had a history of stroke.
Only one of the patients without a history of stroke had factor V Leiden, for a
carrier prevalence of 1.2%.

Although such data do not implicate factor V

Leiden in the genesis of sickle crises, they do not rule out such an interaction
either.
In the few years since its description

there

has been a boom

in

information about the mutation: a Medline' search today for the subject
“factor V Leiden" yields more than 250 results, and there is every indication
that the research will continue.

And with good reason.

In a sense, the story

of factor V Leiden is emblematic of much genetic research in the 1990s: we can
identify the molecular lesion, we can quantify the clinical risks it entails, but
we cannot repair the DNA.

Until that becomes possible, we are obligated to

pursue the mutation's presence in patients with thrombophilia, and make
treatment decisions based on individual risk factors.

Our data indicate that

factor V Leiden is a risk factor that should be considered in both black and
non-black patients.
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